Joshua Schafer
Direttore/Membro del Consiglio presso PHARNEXT SCA
Patrimonio netto: 17 181 $ in data 31/05/2024
Profilo
Joshua Schafer is currently a Director at Pharnext SA, a Director at Shuttle Pharmaceuticals, Inc., a Director at Acer Therapeutics, Inc., an Independent Director at Shuttle Pharmaceuticals Holdings, Inc., an Advisor at DRI Capital, Inc., and the Chief Commercial Officer at Zevra Therapeutics, Inc. He previously worked as the Head-Oncology Franchise at Astellas Pharma, Inc. and as the General Manager-Autoimmune & Rare Disease at Mallinckrodt Pharmaceuticals Ltd.
Mr. Schafer received his undergraduate degree from the University of Notre Dame and his MBA from Northwestern University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ZEVRA THERAPEUTICS, INC.
0.01% | 22/03/2024 | 3 500 ( 0.01% ) | 16 275 $ | 31/05/2024 |
| 14/06/2024 | 1 707 ( 0.01% ) | 906 $ | 31/05/2024 |
Posizioni attive di Joshua Schafer
| Società | Posizione | Inizio |
|---|---|---|
| PHARNEXT SCA | Direttore/Membro del Consiglio | 28/12/2022 |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Direttore/Membro del Consiglio | 01/01/2019 |
| ZEVRA THERAPEUTICS, INC. | Corporate Officer/Principal | 09/01/2023 |
| ACER THERAPEUTICS INC. | Direttore/Membro del Consiglio | 17/11/2023 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Direttore/Membro del Consiglio | - |
DRI Capital, Inc.
 DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Consulente / Consigliere | - |
Precedenti posizioni note di Joshua Schafer
| Società | Posizione | Fine |
|---|---|---|
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Staines Upon Thames, UK and was founded in 2015. | Corporate Officer/Principal | 02/11/2022 |
| ASTELLAS PHARMA INC. | Corporate Officer/Principal | - |
Formazione di Joshua Schafer
| Northwestern University | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| PHARNEXT SCA | Health Technology |
| ASTELLAS PHARMA INC. | Health Technology |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Mallinckrodt Plc, Mallinckrodt Pharmaceuticals Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in Staines Upon Thames, UK and was founded in 2015. | Health Technology |
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
DRI Capital, Inc.
DRI Capital, Inc. Investment ManagersFinance DRI Capital, Inc. (DRI Capital) is a private equity firm, a subsidiary of Persis Holdings Ltd founded in 1992. The firm is headquartered in Toronto, Canada. | Finance |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
- Borsa valori
- Insiders
- Joshua Schafer
